General Pathology — MCQs

General Pathology Indian Medical PG Practice Questions and MCQs

Question 951: Which of the following is a cause of tumorogenesis in aging?

A. Telomerase reactivation (Correct Answer)
B. Telomerase inactivation
C. Increased apoptosis
D. Suppression of proto-oncogenes

Explanation: **Explanation:** The correct answer is **A. Telomerase reactivation.** **1. Why Telomerase Reactivation is correct:** In normal somatic cells, telomeres (repetitive DNA sequences at chromosome ends) shorten with each cell division [2]. Once they reach a critical length, the cell enters **replicative senescence** (the Hayflick limit). However, in the context of aging and tumorigenesis, if a cell bypasses this checkpoint through mutations (like p53 loss), it continues to divide, leading to chromosomal instability [1]. Eventually, the cell must reactivate **Telomerase**, an enzyme that maintains telomere length. This "immortalizes" the cell, allowing for the indefinite proliferation characteristic of cancer. Approximately 85-90% of human cancers show telomerase upregulation [1]. **2. Why the other options are incorrect:** * **B. Telomerase inactivation:** This is a normal physiological process in aging somatic cells that leads to cell death or senescence, thereby acting as a tumor-suppressive mechanism. * **C. Increased apoptosis:** Apoptosis is programmed cell death. Tumorigenesis is characterized by the **evasion of apoptosis** (e.g., via BCL-2 overexpression), not an increase in it. * **D. Suppression of proto-oncogenes:** Proto-oncogenes promote normal growth. Their **activation** (into oncogenes), not suppression, leads to cancer. **Clinical Pearls for NEET-PG:** * **Telomerase** is a specialized reverse transcriptase (TERT) that uses an internal RNA template (TERC). * **ALT (Alternative Lengthening of Telomeres):** A telomerase-independent mechanism used by some tumors (5-10%) to maintain telomeres via DNA recombination [1]. * **Germ cells and Stem cells:** Naturally have high telomerase activity, unlike normal adult somatic cells [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 311-312. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 243-244.

Question 952: Which of the following is/are a product(s) of the lipoxygenase pathway?

A. Prostaglandin
B. Thromboxane A2
C. Leukotrienes (Correct Answer)
D. Prostacyclin

Explanation: **Explanation:** The metabolism of **Arachidonic Acid (AA)** occurs via two major enzymatic pathways: the Cyclooxygenase (COX) pathway and the Lipoxygenase (LOX) pathway [1]. 1. **Why Leukotrienes are correct:** The **5-Lipoxygenase (5-LOX)** enzyme acts on arachidonic acid to produce 5-HPETE, which is subsequently converted into **Leukotrienes (LTs)** [1]. Specifically, LTB4 is a potent chemotactic agent, while LTC4, LTD4, and LTE4 (cysteinyl leukotrienes) cause intense bronchoconstriction and increased vascular permeability [2]. Another branch of the LOX pathway produces **Lipoxins**, which serve as anti-inflammatory mediators. 2. **Why other options are incorrect:** * **Prostaglandins (Option A), Thromboxane A2 (Option B), and Prostacyclin (Option D)** are all products of the **Cyclooxygenase (COX-1 and COX-2)** pathway [2]. * COX converts AA into Prostaglandin G2/H2, which is then converted by specific synthases into PGE2, PGD2, PGF2̱, PGI2 (Prostacyclin), and TxA2 (Thromboxane) [2]. **NEET-PG High-Yield Pearls:** * **Chemotaxis:** LTB4 is one of the most potent chemotactic agents for neutrophils (Mnemonic: **B**4 "**B**rings" neutrophils) [2]. * **Aspirin-Exacerbated Respiratory Disease (AERD):** Inhibiting the COX pathway with Aspirin can "shunt" arachidonic acid toward the LOX pathway, leading to an overproduction of leukotrienes and resulting in bronchospasm [2]. * **Pharmacology Link:** **Zileuton** inhibits 5-Lipoxygenase, while **Montelukast/Zafirlukast** are leukotriene receptor antagonists (CysLT1 receptor) used in asthma management [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 93-94. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, p. 95.

Question 953: SMAC/DIABLO is a:

A. Anti-apoptotic protein
B. Induces necrosis
C. Acts both as anti- and pro-apoptotic protein
D. Pro-apoptotic protein (Correct Answer)

Explanation: **Explanation:** **Smac/DIABLO** (Second mitochondria-derived activator of caspases/Direct IAP-binding protein with low pI) is a critical **pro-apoptotic protein** involved in the intrinsic (mitochondrial) pathway of apoptosis [1]. **1. Why Option D is Correct:** During the intrinsic pathway of apoptosis, mitochondrial outer membrane permeabilization (MOMP) occurs. This leads to the release of several proteins into the cytosol. While **Cytochrome c** activates the apoptosome, **Smac/DIABLO** functions by binding to and neutralizing **IAPs (Inhibitors of Apoptosis Proteins)** [1]. Under normal conditions, IAPs block caspase activity (specifically Caspase-3, 7, and 9) to prevent accidental cell death [1]. By neutralizing these inhibitors, Smac/DIABLO allows the caspase cascade to proceed, thereby promoting apoptosis. **2. Why Other Options are Incorrect:** * **Option A:** Anti-apoptotic proteins include members of the Bcl-2 family like **Bcl-2, Bcl-xL, and Mcl-1**, which stabilize the mitochondrial membrane [1]. Smac/DIABLO does the opposite. * **Option B:** Necrosis is an uncontrolled, passive form of cell death characterized by cell swelling and inflammation. Smac/DIABLO is specifically a mediator of **programmed cell death (apoptosis)** [1]. * **Option C:** Smac/DIABLO has a singular, dedicated role in promoting apoptosis by inhibiting IAPs; it does not exhibit dual or antagonistic functions. **High-Yield Clinical Pearls for NEET-PG:** * **IAPs (Inhibitors of Apoptosis):** Their primary function is to prevent "accidental" apoptosis by inhibiting caspases [1]. * **Mitochondrial "Death" Proteins:** Cytochrome c, Smac/DIABLO, and HtrA2/Omi are all released from the mitochondria to promote apoptosis [1]. * **Pro-apoptotic Bcl-2 family members:** These are categorized into **Effectors** (BAX, BAK) and **BH3-only sensors** (BIM, BID, BAD, PUMA, NOXA). Remember: "Bax and Bak make a puncture in the mitochondria." [1] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-67.

Question 954: Cystic fibrosis is inherited as an autosomal recessive condition. A normal couple has one daughter affected with the disease. They are now planning to have another child. What is the chance of her sibling being affected by the disease?

A. 0
B. 1/2
C. 1/4 (Correct Answer)
D. 3/4

Explanation: ### Explanation **1. Why Option C (1/4) is Correct:** Cystic Fibrosis (CF) follows an **Autosomal Recessive (AR)** inheritance pattern [1]. For a "normal" couple to have an affected child ($aa$), both parents must be asymptomatic **obligate carriers** (genotype $Aa$). According to Mendelian genetics, a cross between two carriers ($Aa \times Aa$) results in the following probabilities for each pregnancy [3]: * **25% (1/4):** Affected ($aa$) * **50% (1/2):** Asymptomatic carriers ($Aa$) * **25% (1/4):** Genotypically normal ($AA$) Since each pregnancy is an independent event, the probability of the next sibling being affected remains **1/4 (25%)** [3]. **2. Why Other Options are Incorrect:** * **Option A (0):** This would only occur if at least one parent was homozygous dominant ($AA$), which is impossible here as they have already produced an affected child. * **Option B (1/2):** This is the risk for an **Autosomal Dominant** condition (if one parent is affected) or the risk of being a **carrier** in an AR condition. * **Option D (3/4):** This is the probability of a child being **unaffected** (1/4 normal + 1/2 carrier) in an AR cross. **3. NEET-PG High-Yield Pearls:** * **CFTR Gene:** Located on **Chromosome 7q**. The most common mutation is **$\Delta$F508** (deletion of phenylalanine) [2]. * **Carrier Frequency:** If the question asks for the probability of a *healthy* sibling being a carrier, the answer is **2/3** (since the affected $aa$ genotype is excluded). * **Diagnosis:** Sweat chloride test ($>60$ mEq/L) is the gold standard. * **Common AR Disorders:** Sickle cell anemia, Thalassemia, Phenylketonuria (PKU), and most enzyme deficiencies [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 150-151. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, p. 476. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 53-54.

Question 955: Which CD marker is characteristic of NK cells?

A. CD16 (Correct Answer)
B. CD60
C. CD32
D. CD25

Explanation: **Explanation:** Natural Killer (NK) cells are innate lymphoid cells that play a crucial role in the host defense against tumors and virally infected cells [1]. They are morphologically identified as **Large Granular Lymphocytes (LGLs)**. **Why CD16 is correct:** NK cells are phenotypically defined by the expression of **CD16** and **CD56**, while being negative for CD3 (a T-cell marker). * **CD16** is the low-affinity Fc receptor for IgG (FcγRIII). It allows NK cells to bind to antibody-coated target cells, leading to **Antibody-Dependent Cellular Cytotoxicity (ADCC)**. * **CD56** (NCAM) is the other primary marker used to identify NK cells in flow cytometry. **Analysis of Incorrect Options:** * **CD60:** This is a carbohydrate antigen (sialylated ganglioside) found on a subset of T-cells and melanocytes; it is not a primary diagnostic marker for NK cells. * **CD32:** Also known as FcγRII, this is an inhibitory receptor found primarily on B-cells, macrophages, and neutrophils, but not typically used to identify NK cells. * **CD25:** This is the alpha chain of the **IL-2 receptor**. It is a classic marker for **Regulatory T-cells (Tregs)** and activated T/B cells, rather than resting NK cells. **High-Yield Clinical Pearls for NEET-PG:** 1. **NK Cell Markers:** CD16, CD56, and CD94. They lack CD3, CD4, and TCR. 2. **Mechanism of Killing:** NK cells use **Perforins** (create pores) and **Granzymes** (induce apoptosis). 3. **Chediak-Higashi Syndrome:** Characterized by a profound defect in NK cell function due to impaired degranulation. 4. **Inhibitory Receptors:** NK cells possess **KIR (Killer Immunoglobulin-like Receptors)** which recognize MHC Class I molecules on healthy cells to prevent "self" destruction [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 200-201.

Question 956: The type of immunological reaction seen in endothelial corneal graft rejection is:

A. Type II
B. Type IV (Correct Answer)
C. Type III
D. Type I

Explanation: **Explanation:** Corneal graft rejection is primarily a **Type IV (Delayed-type) Hypersensitivity reaction** [1]. This is a cell-mediated immune response where the host’s T-lymphocytes (specifically CD4+ Th1 and CD8+ cytotoxic T cells) recognize foreign MHC antigens on the donor corneal endothelium [3]. Upon sensitization, these T cells release cytokines and directly attack the endothelial cells, leading to graft edema and potential failure [3]. **Why other options are incorrect:** * **Type I (Immediate):** Mediated by IgE and mast cell degranulation (e.g., anaphylaxis, asthma). It is not involved in solid organ or tissue rejection. * **Type II (Antibody-mediated):** Involves IgG/IgM antibodies binding to cell surface antigens (e.g., Hyperacute rejection in vascularized organs like the kidney). Since the cornea is avascular, pre-formed antibodies rarely reach the graft to cause this reaction. * **Type III (Immune-complex):** Caused by the deposition of antigen-antibody complexes in tissues (e.g., SLE, Arthus reaction). It does not play a primary role in corneal rejection. **High-Yield Clinical Pearls for NEET-PG:** * **Avascularity:** The cornea is an "immunologically privileged site" due to its lack of blood vessels and lymphatics, which usually prevents sensitization. * **Khodadoust Line:** A pathognomonic clinical sign of endothelial rejection consisting of a line of inflammatory cells (precipitates) on the corneal endothelium. * **Hyperacute Rejection:** Always Type II hypersensitivity (occurs within minutes). * **Acute/Chronic Rejection:** Primarily Type IV hypersensitivity (occurs days to years later) [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 173-175. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 216-218. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 240.

Question 957: Which of the following conditions exhibits autosomal inheritance?

A. Hemophilia
B. Marfan syndrome (Correct Answer)
C. Congenital Heart Disease (CHD)
D. Gout

Explanation: **Explanation:** **Marfan Syndrome (Correct Answer):** Marfan syndrome is a classic example of an **Autosomal Dominant** disorder [1]. It is caused by a mutation in the **FBN1 gene** on chromosome 15, which encodes **Fibrillin-1**, a glycoprotein essential for the structural integrity of the extracellular matrix and the regulation of TGF-β signaling [1]. Since it is autosomal, the gene is located on a non-sex chromosome, and being dominant, a single mutated allele is sufficient to manifest the disease [1]. **Analysis of Incorrect Options:** * **Hemophilia (A):** This is an **X-linked recessive** disorder (Hemophilia A involves Factor VIII; Hemophilia B involves Factor IX) [2]. It primarily affects males, while females are typically asymptomatic carriers [2]. * **Congenital Heart Disease (C):** Most CHDs are **multifactorial** in origin, involving a complex interaction between multiple susceptibility genes and environmental triggers (e.g., rubella, alcohol). While some are associated with chromosomal anomalies (like Down syndrome), they do not follow a simple Mendelian autosomal inheritance pattern. * **Gout (D):** Primary gout is considered a **polygenic/multifactorial** metabolic disorder influenced by diet, lifestyle, and multiple genes regulating urate transport and excretion. **NEET-PG High-Yield Pearls:** * **Marfan Syndrome Triad:** Skeletal abnormalities (arachnodactyly, pectus excavatum), Ocular changes (**Ectopia lentis**—typically upward dislocation), and Cardiovascular lesions (**Aortic root dilation/dissection**) [1]. * **Mnemonic for Chromosome:** Marfan has **15** letters = Chromosome **15**. * **Steinberg Sign & Walker-Murdoch Sign:** Clinical tests for joint hypermobility/arachnodactyly specific to Marfan syndrome. * **Differential:** Homocystinuria also presents with marfanoid habitus but features **downward** lens dislocation and intellectual disability. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 153-154. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, p. 151.

Question 958: Delicate, brown or black pigmented non-carious plaque found on the enamel at the cervical margin of the tooth is:

A. Burtonian line
B. Argyria
C. Bismuth line
D. Mesenteric line (Correct Answer)

Explanation: **Explanation:** The correct answer is **Mesenteric line** (also known as the "black stain" or "Pickering’s line"). This is a specific type of extrinsic dental plaque characterized by a delicate, dark, non-carious line found on the enamel surface, typically following the cervical margin of the teeth. **1. Why Mesenteric Line is Correct:** The Mesenteric line is caused by the interaction between hydrogen sulfide-producing bacteria (such as *Actinomyces*) and iron in the saliva or gingival crevicular fluid. This reaction forms **ferric sulfide**, which precipitates as a black pigment. Clinically, it is significant because it is firmly attached to the tooth but is associated with a **lower incidence of dental caries**, likely due to the presence of calcium and phosphate salts in the plaque [1]. **2. Why Other Options are Incorrect:** * **Burtonian line:** This is a bluish-purple line on the gums (gingival margin) caused by **chronic lead poisoning** [3]. It results from the reaction of lead with sulfur produced by oral bacteria [2]. * **Argyria:** This refers to a systemic condition caused by chronic exposure to **silver** compounds, leading to a characteristic blue-gray discoloration of the skin and mucous membranes, not a localized dental plaque. * **Bismuth line:** Similar to the Burtonian line, this is a dark blue or black line on the gingiva caused by **bismuth poisoning**. **Clinical Pearls for NEET-PG:** * **Lead (Burtonian line):** Blue-purple gingival line [3]. * **Mercury:** Pinkish-red gingiva (Acrodynia/Pink disease) [2]. * **Bismuth:** Black gingival line. * **Mesenteric line:** Black **enamel** stain (not gingival), associated with **low caries index** [1]. * **Copper:** Greenish-brown stains on teeth. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 734-735. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 133-134. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Infectious Diseases, pp. 418-419.

Question 959: Angelman syndrome is due to what type of genetic mechanism?

A. Digenic inheritance
B. Inversions
C. Uniparental disomy (Correct Answer)
D. Mitochondrial disorder

Explanation: **Explanation:** Angelman syndrome is a classic example of **Genomic Imprinting**, a process where certain genes are expressed in a parent-of-origin-specific manner [1]. The syndrome results from the loss of the maternal contribution of the **UBE3A gene** located on chromosome **15q11-q13** [1]. **Why Uniparental Disomy (UPD) is correct:** While the most common cause of Angelman syndrome is a maternal deletion (approx. 70%), **Paternal Uniparental Disomy** (where a child inherits two copies of chromosome 15 from the father and none from the mother) accounts for about 3-5% of cases. Since the paternal UBE3A gene is normally silenced (imprinted), having two paternal copies results in a total lack of active UBE3A expression in the brain, leading to the syndrome [1]. **Analysis of Incorrect Options:** * **Digenic inheritance:** Refers to diseases caused by the co-inheritance of mutations in two different genes (e.g., Retinitis pigmentosa). * **Inversions:** These are chromosomal rearrangements where a segment is reversed. While they can cause genetic disruption, they are not the primary mechanism for Angelman syndrome. * **Mitochondrial disorder:** These are inherited exclusively from the mother (maternal inheritance) and typically affect high-energy tissues (e.g., MELAS, LHON) [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Features:** Often referred to as **"Happy Puppets"** due to frequent laughter, jerky movements (ataxia), seizures, and severe intellectual disability [1]. * **Prader-Willi Syndrome (PWS):** The "sister" condition caused by loss of the **paternal** 15q11-q13 (often via Maternal UPD) [1]. * **Mnemonic:** **A**ngelman = **M**aternal loss (**A**lways **M**ad/Happy); **P**rader-Willi = **P**aternal loss. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 181-182. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, p. 177.

Question 960: Pearl's stain is used to demonstrate which of the following in tissues?

A. Hemosiderin (Correct Answer)
B. Fat
C. Reticulin
D. Fibrin

Explanation: **Explanation:** **Perl’s Prussian Blue** is the gold standard histochemical stain used to demonstrate **Hemosiderin** (ferric iron) in tissue sections [1]. 1. **Why Hemosiderin is correct:** Hemosiderin is an intracellular storage form of iron [2]. In this reaction, the tissue is treated with a mixture of potassium ferrocyanide and dilute hydrochloric acid. The acid releases ferric ions ($Fe^{3+}$) from the hemosiderin, which then react with the potassium ferrocyanide to form an insoluble bright blue pigment called **ferric ferrocyanide** (Prussian blue) [1]. This allows for the visualization of iron in conditions like hereditary hemochromatosis, hemosiderosis, or around areas of old hemorrhage [1], [2]. 2. **Why the other options are incorrect:** * **Fat:** Demonstrated using **Sudan Black B** or **Oil Red O**. These require frozen sections because routine processing (using alcohols and xylene) dissolves lipids. * **Reticulin:** Demonstrated using **Silver stains** (e.g., Gomori’s or Gordon and Sweets). Reticulin fibers are argyrophilic (silver-loving). * **Fibrin:** Best visualized using **Martius Scarlet Blue (MSB)** or **Mallory’s Phosphotungstic Acid Hematoxylin (PTAH)**, where it appears deep blue/purple. **High-Yield Clinical Pearls for NEET-PG:** * **Perl’s stain does NOT stain Ferritin** (only hemosiderin) because ferritin does not have the same reactive iron density. * **Hallervorden-Spatz disease:** Perl’s stain is used to show iron deposition in the Globus Pallidus. * **Sideroblastic Anemia:** Used to identify "Ringed Sideroblasts" in bone marrow aspirates [3]. * **Heart Failure Cells:** Perl’s stain identifies hemosiderin-laden macrophages in the lungs, indicating chronic pulmonary congestion. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 854-855. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 75-76. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 257-258.

Practice by Chapter

Cell Injury and Cell Death

Practice Questions

Adaptations of Cellular Growth

Practice Questions

Accumulations and Deposits

Practice Questions

Acute and Chronic Inflammation

Practice Questions

Tissue Repair and Wound Healing

Practice Questions

Hemodynamic Disorders

Practice Questions

Genetic Disorders

Practice Questions

Environmental Pathology

Practice Questions

Nutritional Diseases

Practice Questions

Molecular Basis of Disease

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free